title: [An update on glucocorticoid-induced osteoporosis].
abstract: Glucocorticoid-induced osteoporosis is the most common cause of secondary osteoporosis. Moreover, it is the most common reason for an osteoporosis among young adults. The clinical use of oral glucocorticoids increases the fracture incidence already within three months after starting the therapy. There does not seem to be a lower threshold: even doses as low as 2,5 mg of prednisone equivalent increase the risk of fractures. Adequate diagnostic and therapy are able to significantly reduce the resulting fracture risk. This article will discuss the pathophysiology of glucocorticoid-induced osteoporosis and give a summary of the current recommendations including the recently updated German guidelines.
authors.forename: Marco
authors.initials: M
authors.lastname: Krasselt
authors.forename: Christoph
authors.initials: C
authors.lastname: Baerwald
mesh_terms: D000284:Administration, Oral; D015519:Bone Density / Q000187:drug effects; D002136:Calcium, Dietary / Q000627:therapeutic use; D002762:Cholecalciferol / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005938:Glucocorticoids / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008134:Long-Term Care; D010024:Osteoporosis / Q000139:chemically induced* / Q000175:diagnosis; D058866:Osteoporotic Fractures / Q000139:chemically induced; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use; D012306:Risk; D055815:Young Adult
chemical_list: D002136:Calcium, Dietary; D005938:Glucocorticoids; D002762:Cholecalciferol; D011239:Prednisolone